Parker Hughes Cancer Center

Press Releases  


Parker Hughes Institute scientists develop anti-aids drugs against multidrug resistant HIV

May 2, 2000, Saint Paul, Minn. Formally designated as a threat to U.S. national security, AIDS is expected to rise for a decade before there is much prospect of improvement. It is known that the main reason available drug treatments fail in AIDS patients is the emergence of multidrug resistance. Therefore, new agents that are effective against these multidrug resistant strains of the HIV virus are urgently needed. Researchers at the St. Paul, Minn.-based Parker Hughes Institute have developed two new classes of anti-AIDS drugs that overcome multidrug resistance.

The two new classes of anti-AIDS drugs, thiophene-ethyl thiourea compounds and aryl phosphate derivatives of d4T, are extremely potent against all forms of the HIV virus. The United States Patent Office issued two patents covering these drugs and the methods in which to use them.

The prototype drugs, HI-113 and HI-443, offer new hope for patients suffering from AIDS because the drugs are at least 10,000 times more active than available anti-AIDS drugs. The drugs are being produced in large scale for clinical trial use within the next nine months.

The Parker Hughes Institute, located in Roseville, Minnesota, is a non-profit research organization dedicated to combating cancer, AIDS, and diseases of the immune system.